



May 16, 2025

Ref:- GHL/2025-26/EXCH/17

The General Manager
Dept. of Corporate Services
BSE Limited,
P J Towers, Dalal Street,
Mumbai - 400 001

The Manager
Listing Department
National Stock Exchange of India Limited
Exchange Plaza, C-1, Block G,
Bandra Kurla Complex,
Bandra (E), Mumbai - 400 051

Scrip Code: 543654

Symbol: MEDANTA

Sub: Newspaper Publication - Audited Financial Results of the Company for the fourth Quarter and financial year ended March 31, 2025.

Dear Sir(s),

Pursuant to Regulation 30 and 47 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed herewith, the copies of Newspaper clippings of the Audited Financial Results of the Company, for the fourth quarter and financial year ended March 31, 2025, published in Financial Express (English) and Jansatta (Hindi) on Friday, May 16, 2025.


This is for your information and record.

Thanking You,

For Global Health Limited

Rahul Ranjan
Company Secretary & Compliance Officer
M. No. A17035

Encl: a/a



Small IT firms go big on deal wins

● Outpace bigger peers in delivering large contracts

PADMINI DHURVARAJ
Bengaluru, May 15

MID-SIZED IT SERVICES companies are emerging as strong contenders in securing and delivering large contracts, a space historically dominated by larger peers. Firms such as Coforge, LTIMindtree and Persistent Systems have reported significant wins and revenue growth in FY25, in contrast with the more subdued performance of major firms like Tata Consultancy Services (TCS), Infosys, and HCLTech.

Coforge signed a \$1.56-billion, 13-year contract with Texas-based Sabre, making it the only domestic mid-tier IT firm to close a mega deal in FY25. In the March quarter, it reported \$2.1 billion in new orders, its highest to date. It has also expanded its client base in higher revenue segments, including the \$5-10 million and \$10 million-plus brackets.

LTIMindtree recently recorded its largest deal, a \$450-million seven-year contract with a global agribusiness company. Sonata Software secured a \$73-million deal in the TMT sector, and L&T Technology Services posted its highest-ever bookings in the March quarter, which

DEAL DIARIES

■ Coforge signed a **\$1.56-bn**, 13-year contract with Texas-based Sabre, making it the only domestic mid-tier IT firm to close a mega deal in FY25

■ LTIMindtree recently recorded its largest deal, a **\$450-mn** 7-year contract with a global agribusiness firm

■ Sonata Software bagged a **\$73-mn** deal in TMT sector, while L&T Tech posted its highest-ever bookings in March quarter

■ Though larger companies have secured substantial contracts, they have offered conservative guidance for FY26 amid US tariff and other concerns

included contracts worth \$80 million and \$50 million.

These developments translated into faster growth. In FY25, mid-tier firms such as Mphasis, Hexaware, Persistent Systems and Coforge reported revenue growth of 7-32%. This outpaced top-tier competitors, with TCS, Infosys, and HCLTech posting around 4% growth, and Wipro reporting a 2% decline.

The fourth quarter also reflected this. Coforge posted a 4.7% sequential growth in Q4, with ₹3,410-crore revenue. L&T's grew 12.4% to ₹2,982.4 crore. In contrast, the top-tier firms missed revenue estimates despite announcing sizable deals.

Analysts attribute the performance of mid-tier firms to quicker decision-making, steady leadership and early adoption of GenAI. Kotak Institutional Equities said newer technologies

tend to favour more agile firms.

Stable leadership has also played a role. CEOs at Coforge and Persistent have been in place for over 5 years, compared with recent changes at TCS, Wipro and Tech Mahindra. This is seen as contributing to more consistent execution. Clients are also opting for smaller, flexible contracts. These are typically more aligned with the capabilities of mid-tier firms, allowing them to grow their presence in digital transformation programmes.

Larger firms, while still securing substantial contracts, have offered conservative guidance for FY26 amid macroeconomic concerns. TCS reported \$12.2-billion deal wins in Q4, up from \$10.2 billion in Q3, but growth forecast remains tempered due to factors such as global tariff issues and constrained discretionary spending.

Pernod loses bid for Delhi licence again

THE DELHI GOVERNMENT has rejected for a third time Pernod Ricard's request for a licence to sell its brands, citing ongoing investigations, an order showed.

The order comes despite an appeals authority in February asking officials to reconsider the rejections as investigations against Pernod for allegedly breaching the city's liquor pol-

icy in 2021 had not so far resulted in any conviction.

Delhi authorities disagreed and rejected Pernod's request again in a May 9 order, saying courts had upheld that local governments have "broad discretion to deny it (a licence) to entities that lack moral probity".

"Mere existence of allegations and investigation justifies

administrative caution in licensing matters," Delhi excise commissioner Sunny K Singh wrote in his order.

The order is not public but was reviewed by Reuters on Thursday.

"We will continue to pursue all legal avenues available to us," the French liquor giant said.

QUARTERLY SCORECARD

ITC Hotels Q4 net profit up 19% on higher revenues

PRESS TRUST OF INDIA
New Delhi, May 15


ITC HOTELS ON Thursday reported a 19% rise in consolidated net profit at ₹257.85 crore in the March quarter on the back of higher revenues.

The company had posted a consolidated net profit of ₹216 crore in the same quarter of the previous fiscal, ITC Hotels said in a regulatory filing.

Consolidated revenue from operations during the quarter stood at ₹1,060.62 crore against ₹1,015.4 crore in the year-ago period, the company added.

Total expenses in the quarter under review were marginally higher at ₹749.81 crore as compared to ₹740.41 crore in the corresponding period a year ago.

During the 2024-25, the consolidated net profit was at ₹637.64 crore as compared to



Total expenses in the March quarter were marginally higher at ₹749.81 cr compared to ₹740.41 cr in the corresponding period a year ago

₹423.87 crore in FY24.

In FY25, the company's consolidated revenue from operations was at ₹3,559.81 crore compared to ₹2,224.4 crore in FY24.

JSW Energy profit up 16% to ₹408 cr



JSW ENERGY ON Thursday posted a 16% rise in its consolidated net profit of ₹408 crore in the March quarter compared to a year ago, aided by contributions from KSK Mahanadi thermal project and organic wind capacity additions.

—PTI

Arvind records 48% rise in profit



TEXTILE AND APPAREL major Arvind reported a 48% rise in consolidated net profit at ₹154.6 crore in the fourth quarter, driven by volume growth in textiles.

—PTI

Godfrey Phillips profit rises 31%



CIGARETTE MAKER GODFREY PHILLIPS India reported a 30.73% rise in its consolidated net profit to ₹293.96 crore in the March quarter.

—PTI

Zepto bets on monetising brand insights with Atom

AYANTI BERA
Bengaluru, May 15

THE ROLL-OUT OF Zepto Atom, a subscription-based analytics tool for consumer brands on its platform, marks a significant step in its broader monetisation strategy. Atom offers granular data insights to brands on customer behaviour, market share, conversions, and hyperlocal trends. An upgraded version of Zepto's existing brand portal, it will be available as a paid add-on for performance tracking.

The firm said it will onboard brand partners onto Atom starting this week, beginning with a webinar scheduled for Friday.

The launch comes at a time when investor focus is shifting to profitability in the quick-commerce space, where players like Zepto and Swiggy Instamart are yet to break even.

Abhishek Maiti, director—industrial goods and services at market intelligence firm 1Latice, told FE that brands can better manage inventory by understanding what sells where and reducing stock-outs and supply chain inefficiencies. Firms can also gain sharper visibility into consumer behaviour at the neighbourhood level, tailoring offerings and price points to match local demand, he said.

With plans for an IPO, the Atom product adds a new revenue lever to Zepto's business model. The firm claims it will help marketers understand product performance at a granular level and make campaign adjustments in real time.

Maiti, however, said several challenges could limit its adoption and utility. For one, the data is confined to Zepto's own ecosystem, offering no visibility into the performance across other quick-commerce or retail channels. "With such platforms being a subscription-based service, smaller brands with limited budgets may find the recurring costs a costly affair."

Zepto, like Blinkit and Swiggy Instamart, is also turning to ad revenues as a meaningful revenue stream. Such ad sales may become meaningful contributors to gross margins over time, provided adoption scales, say analysts.

Kaynes Technology India Limited



Regd. Off. 23-25, Belagola Food Industrial Estate, Metagalli P.O., Mysore-570 016, Karnataka, India
website: www.kaynestech.com email: kaynestechcs@kaynestech.com
Corporate Identity Number: L29128KA2008PLC045825. Telephone No: +91 8212582595

EXTRACT OF THE AUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER AND THE YEAR ENDED 31ST MARCH 2025

(Rs. in million, except per share data)

Particulars	Quarter ended			Year ended	Year ended
	31 st March 2025	31 st December 2024	31 st March 2024	31 st March 2025	31 st March 2024
	(Audited)	(Unaudited)	(Audited)	(Audited)	(Audited)
Revenue from operations	9,844.83	6,611.75	6,373.04	27,217.52	18,046.19
Net profit before exceptional items and tax	1,419.32	808.48	1,019.31	3,716.24	2,315.69
Net profit before tax	1,419.32	808.48	1,019.31	3,716.24	2,315.69
Net profit from ordinary activities after tax	1,162.02	664.62	812.59	2,934.33	1,832.89
Total comprehensive income for the period attributable to shareholders [comprising profit for the period (after tax) and other comprehensive income (after tax)]	1,168.68	668.68	816.54	2,944.11	1,838.51
Paid-up equity share capital (Face value of Rs.10 each)	640.84	640.11	639.18	640.84	639.18
Earnings per share	(not annualised)	(not annualised)	(not annualised)	(annualised)	(annualised)
(a) Basic	18.12	10.39	13.13	45.82	30.63
(b) Diluted	17.99	10.28	12.97	45.40	30.24

1) Key standalone financial information

Particulars	Quarter ended			Year ended	Year ended
	31 st March 2025	31 st December 2024	31 st March 2024	31 st March 2025	31 st March 2024
	(Audited)	(Unaudited)	(Audited)	(Audited)	(Audited)
Revenue from operations	7,365.46	3,958.98	3,746.32	19,154.43	12,739.39
Profit before tax	776.15	525.88	647.49	2,753.48	1,606.00
Profit after tax	604.09	380.35	496.99	2,099.05	1,260.98

- The statement of audited standalone and consolidated financial results ("the Statements") of Kaynes Technology India Limited ("the Company") for the quarter and year ended 31st March 2025 have been reviewed by the Audit Committee and approved by the Board of Directors of the Company at their meetings held on 15th May 2025. The above Statements have been subjected to audit by the Statutory Auditors of the Company. The reports of the Statutory Auditors are unqualified.
- The Statements have been prepared in accordance with Indian Accounting Standards ("Ind AS") prescribed under section 133 of The Companies Act, 2013 and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
- The above is an extract of the detailed format of audited financial results filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the audited financial results are available on the Stock Exchanges' websites, www.nseindia.com and www.bseindia.com and on the Company's website www.kaynestech.com. and the same can also be accessed by scanning the QR code provided.

By Order of the Board

For Kaynes Technology India Limited

Sd/-

Savitha Ramesh

DIN: 01756684

Whole Time Director & Chairperson





Global Health Limited
CIN: L85110DL2004PLC128319

Regd. Office: Medanta Mediclinic, E-18, Defence Colony, New Delhi - 110024, India
Corp. Office: Medanta - The Medicity, Sector - 38, Gurugram, Haryana 122001, India
Tel: +91 124 483 4060 | E-mail: compliance@medanta.org | Website: <https://www.medanta.org>

EXTRACT OF CONSOLIDATED AUDITED FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED 31 MARCH 2025

(₹ in Millions except EPS)

Sl. No.	Particulars	Quarter ended	Quarter ended	Year ended	Year ended
		31.03.2025	31.03.2024	31.03.2025	31.03.2024
		(Audited)	(Audited)	(Audited)	(Audited)
1	Revenue from operations	9,312.47	8,086.31	36,923.15	32,751.11
2	Net profit for the period (before tax and exceptional items)	1,833.34	1,430.87	6,971.53	6,270.99
3	Net profit for the period before tax (after exceptional items)	1,334.38	1,430.87	6,472.57	6,270.99
4	Net profit for the period after tax (after exceptional items)	1,013.78	1,273.47	4,813.18	4,780.60
5	Total comprehensive income for the period [comprising profit for the period (after tax) and other comprehensive income (after tax)]	991.04	1,273.38	4,806.48	4,771.22
6	Paid up equity share capital	537.17	537.01	537.17	537.01
7	Reserves (excluding Revaluation Reserve)	33,326.93	28,519.26	33,326.93	28,519.26
8	Earnings Per Share (of Rs 2/- each) -				
	Basic:	3.77	4.74	17.92	17.80
	Diluted:	3.77	4.74	17.92	17.80

EXTRACT OF STANDALONE AUDITED FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED 31 MARCH 2025

(₹ in Millions)

Sl. No.	Particulars	Quarter ended	Quarter ended	Year ended	Year ended
		31.03.2025	31.03.2024	31.03.2025	31.03.2024
		(Audited)	(Audited)	(Audited)	(Audited)
1	Revenue from operations	8,028.68	7,242.69	32,041.46	29,747.24
2	Net profit for the period (before tax and exceptional items)	1,757.83	1,486.34	6,729.43	6,588.52
3	Net profit for the period before tax (after exceptional items)	1,258.87	1,486.34	6,230.47	6,588.52
4	Net profit for the period after tax (after exceptional items)	934.12	1,094.31	4,615.28	4,863.51
5	Total comprehensive income for the period [comprising profit for the period (after tax) and other comprehensive income (after tax)]	911.52	1,093.93	4,605.60	4,853.25

Notes:

- These results have been reviewed and recommended by the Audit Committee and accordingly approved by the Board of Directors of the Company at their respective meetings held on 15 May 2025.
- The above is an extract of the detailed format of Financial Results filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015. The full format of the consolidated and standalone Quarterly Financial Results are available on the Stock Exchange websites (www.bseindia.com and www.nseindia.com) and also available at the company's website <https://www.medanta.org>.

Place: Gurugram

Date: 15 May 2025



By order of the Board

for Global Health Limited

Sd/-

Dr. Naresh Trehan

Chairman and Managing Director

